VIZZ Eye Drops: The "Pupil-Selective" Game Changer
With a 71% responder rate and 10-hour duration, VIZZ represents a genuine breakthrough in presbyopia treatment. Here's why eye care professionals are calling it a different class of drug entirely.
Drug
Aceclidine 1.44%
Manufacturer
Lenz Therapeutics
Approved
Jul 2025
Duration
~10 hours
Why Aceclidine Is Different
Unlike pilocarpine (used in Vuity and Qlosi), aceclidine is a "pupil-selective" muscarinic agonist.[PMC] This means it constricts the pupil (iris sphincter) without significantly stimulating the ciliary muscle. This single difference explains why VIZZ has:
- Less headache: No ciliary spasm → no brow ache
- Less dim vision: More controlled pupil constriction without myopic shift
- Longer duration: Stable pupil size for ~10 hours
- No accommodation interference: Distance vision preserved
Aceclidine has been used in European ophthalmology since the 1960s for glaucoma treatment,[PMC] but Lenz Therapeutics was the first to develop a modern ophthalmic formulation optimized for presbyopia.[LENZ]
CLARITY Trial Results
VIZZ's approval was based on three Phase III trials — CLARITY-1, CLARITY-2, and CLARITY-3 — representing the most comprehensive dataset of any presbyopia drop.[FDA]
CLARITY-2 Key Results
Sources: Trinidad Vision, Drug Discovery News
The most striking number is the NNT of ~2. For every two patients who try VIZZ, one achieves clinically significant near-vision improvement. Compare this to Vuity's NNT of 5-11, and the clinical advantage is clear.[Trinidad Vision]
Post-LASIK and Post-Cataract Results
VIZZ is the first presbyopia drop with strong clinical data in post-surgical patients.[Trinidad Vision] These "plano-presbyopes" — people with excellent distance vision (often from prior LASIK) who now need reading glasses — are a large, highly motivated population. VIZZ works because it doesn't interfere with the refractive correction already in place; it purely extends depth of focus through controlled miosis.
Unique Dosing Protocol
VIZZ Two-Drop Protocol
- 1. Instill one drop in each eye
- 2. Wait exactly 2 minutes
- 3. Instill a second drop from the same single-use vial
- 4. Once daily dosing — no need for a second dose later
This protocol is designed to maximize aceclidine bioavailability while maintaining pupil selectivity.[FDA]
副作用
VIZZ's pupil-selective mechanism translates directly into a milder side effect profile compared to pilocarpine drops:
User reports note that the VIZZ formulation is thick and sometimes difficult to dispense from the single-use vials, occasionally leading to wasted doses.[Reddit] The eye redness can give a "stoned" appearance for approximately an hour after instillation.[Reddit]
For the full safety analysis including retinal detachment risk, drug interactions, and long-term considerations, see our comprehensive side effects guide.
The Bottom Line
VIZZ represents a genuine generational leap in presbyopia pharmacotherapy. The combination of pupil selectivity, high responder rate, 10-hour duration, and proven post-LASIK efficacy makes it the clinical frontrunner as of 2026.
Best for:
- • Post-LASIK patients needing near vision correction
- • Patients who experienced headaches with Vuity
- • Active professionals who need all-day near vision
- • Ages 40-55 with mild to moderate presbyopia
For even better results, consider combining VIZZ with Gabor patch brain training — drops fix the optics while training fixes the neural processing. Read the full comparison →
Primary Sources
- • LENZ Therapeutics: VIZZ FDA Approval Press Release
- • FDA: Drug Trials Snapshots — VIZZ
- • PMC: FDA Approval of Aceclidine — A New Chapter in Nonsurgical Presbyopia
- • PMC: Pharmacological Pinhole in Presbyopia — From Pilocarpine to Aceclidine
- • The Ophthalmologist: FDA Approve Presbyopia Treatment First
- • Trinidad Vision: VIZZ — What Patients Should Know
- • Drug Discovery News: Age-Related Vision Changes, No Glasses Needed